Samsung Biologics Co.,Ltd.

KOSE:A207940 Stock Report

Market Cap: ₩72.2t

Samsung BiologicsLtd Valuation

Is A207940 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A207940 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
₩493.79k
Fair Value
105.6% overvalued intrinsic discount
25
Number of Analysts

Below Fair Value: A207940 (₩1015000) is trading above our estimate of fair value (₩493785.24)

Significantly Below Fair Value: A207940 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A207940?

Key metric: As A207940 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for A207940. This is calculated by dividing A207940's market cap by their current earnings.
What is A207940's PE Ratio?
PE Ratio68.6x
Earnings₩1.05t
Market Cap₩72.24t

Price to Earnings Ratio vs Peers

How does A207940's PE Ratio compare to its peers?

The above table shows the PE ratio for A207940 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average66.6x
LONN Lonza Group
69.9x21.0%CHF 40.0b
A Agilent Technologies
32.6x8.2%US$42.1b
A223250 DreamCIS
15.1xn/a₩71.2b
A326030 SK Biopharmaceuticals
148.8x51.1%₩8.6t
A207940 Samsung BiologicsLtd
68.6x14.4%₩72.2t

Price-To-Earnings vs Peers: A207940 is expensive based on its Price-To-Earnings Ratio (68.6x) compared to the peer average (66.6x).

Price to Earnings Ratio vs Industry

How does A207940's PE Ratio compare vs other companies in the Asian Life Sciences Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
A207940 68.6xIndustry Avg. 33.4xNo. of Companies7PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: A207940 is expensive based on its Price-To-Earnings Ratio (68.6x) compared to the Asian Life Sciences industry average (33.4x).

Price to Earnings Ratio vs Fair Ratio

What is A207940's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A207940 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio68.6x
Fair PE Ratio29x

Price-To-Earnings vs Fair Ratio: A207940 is expensive based on its Price-To-Earnings Ratio (68.6x) compared to the estimated Fair Price-To-Earnings Ratio (29x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst A207940 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₩1,015,000.00
₩1,224,580.00
+20.6%
11.8%₩1,400,000.00₩733,500.00n/a25
Jan ’26₩949,000.00
₩1,215,380.00
+28.1%
12.1%₩1,400,000.00₩733,500.00n/a25
Dec ’25₩975,000.00
₩1,213,250.00
+24.4%
11.9%₩1,400,000.00₩733,500.00n/a26
Nov ’25₩998,000.00
₩1,210,180.00
+21.3%
12.5%₩1,400,000.00₩733,500.00n/a25
Oct ’25₩977,000.00
₩1,074,392.00
+10.0%
11.1%₩1,250,000.00₩709,800.00n/a25
Sep ’25₩980,000.00
₩1,059,607.69
+8.1%
10.5%₩1,250,000.00₩709,800.00n/a26
Aug ’25₩925,000.00
₩1,037,029.63
+12.1%
9.8%₩1,250,000.00₩709,800.00n/a27
Jul ’25₩759,000.00
₩1,021,411.54
+34.6%
10.3%₩1,250,000.00₩688,700.00n/a26
Jun ’25₩730,000.00
₩1,032,833.33
+41.5%
7.8%₩1,250,000.00₩780,000.00n/a24
May ’25₩781,000.00
₩1,032,833.33
+32.2%
7.8%₩1,250,000.00₩780,000.00n/a24
Apr ’25₩816,000.00
₩1,038,181.82
+27.2%
8.4%₩1,250,000.00₩750,000.00n/a22
Mar ’25₩774,000.00
₩1,027,510.17
+32.8%
8.7%₩1,250,000.00₩750,000.00n/a23
Feb ’25₩829,000.00
₩1,035,309.36
+24.9%
8.7%₩1,250,000.00₩750,000.00n/a25
Jan ’25₩760,000.00
₩1,035,309.36
+36.2%
9.8%₩1,250,000.00₩720,000.00₩949,000.0025
Dec ’24₩711,000.00
₩1,035,309.36
+45.6%
9.8%₩1,250,000.00₩720,000.00₩975,000.0025
Nov ’24₩703,000.00
₩1,036,780.58
+47.5%
9.9%₩1,250,000.00₩720,000.00₩998,000.0024
Oct ’24₩681,000.00
₩1,052,292.78
+54.5%
9.3%₩1,250,000.00₩770,000.00₩977,000.0023
Sep ’24₩733,000.00
₩1,058,030.58
+44.3%
7.7%₩1,160,000.00₩770,000.00₩980,000.0024
Aug ’24₩802,000.00
₩1,068,951.31
+33.3%
8.1%₩1,200,000.00₩770,000.00₩925,000.0026
Jul ’24₩744,000.00
₩1,082,766.62
+45.5%
8.8%₩1,200,000.00₩770,000.00₩759,000.0026
Jun ’24₩788,000.00
₩1,082,766.62
+37.4%
8.8%₩1,200,000.00₩770,000.00₩730,000.0026
May ’24₩781,000.00
₩1,091,228.15
+39.7%
8.6%₩1,200,000.00₩770,000.00₩781,000.0026
Apr ’24₩788,000.00
₩1,101,612.77
+39.8%
8.7%₩1,300,000.00₩770,000.00₩816,000.0026
Mar ’24₩773,000.00
₩1,112,211.86
+43.9%
8.7%₩1,300,000.00₩770,000.00₩774,000.0028
Feb ’24₩804,000.00
₩1,114,711.86
+38.6%
8.8%₩1,300,000.00₩770,000.00₩829,000.0028
Jan ’24₩821,000.00
₩1,111,055.65
+35.3%
8.2%₩1,300,000.00₩830,000.00₩760,000.0026
Analyst Price Target
Consensus Narrative from 25 Analysts
₩1.22m
Fair Value
17.1% undervalued intrinsic discount
25
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/20 10:36
End of Day Share Price 2025/01/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Samsung Biologics Co.,Ltd. is covered by 47 analysts. 24 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Girish BakhruBofA Global Research
Jun LimCGS International
Hyeryeong KimCGS International